ellaturner  created a new article
8 w

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis | #gene editing therapies

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis

With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR